Panacea Life Sciences Holdings annual stock-based compensation
2014
2015
2016
2017
2018
2019
2020
Panacea Life Sciences Holdings Stock-Based Compensation Growth & History (PLSH)
Panacea Life Sciences Holdings's stock-based compensation was $1.4M for fiscal 2020.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-12-31 | $1.4M | −$2.4M | −64.18% |
| 2019 | 2019-12-31 | $3.8M | $2.9M | +323.13% |
| 2018 | 2018-12-31 | $892,073 | $892,073 | — |
| 2017 | 2017-12-31 | $0 | −$100,000 | — |
| 2016 | 2016-12-31 | $100,000 | $95,000 | +1900.00% |
| 2015 | 2015-12-31 | $5,000 | −$50,010 | −90.91% |
| 2014 | 2014-12-31 | $55,010 | — | — |
Panacea Life Sciences Holdings quarterly stock-based compensation
Q2.14
Q3.14
Q2.15
Q3.15
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2021 | 2021-03-31 | −$3.4M | −$4.0M | — |
| Q4 2020 | 2020-12-31 | $142,674 | −$1.3M | −89.80% |
| Q3 2020 | 2020-09-30 | $186,068 | −$106,344 | −36.37% |
| Q2 2020 | 2020-06-30 | $386,011 | $308,234 | +396.30% |
| Q1 2020 | 2020-03-31 | $637,292 | −$1.4M | −68.23% |
| Q4 2019 | 2019-12-31 | $1.4M | $1.1M | +378.58% |
| Q3 2019 | 2019-09-30 | $292,412 | $192,577 | +192.90% |
| Q2 2019 | 2019-06-30 | $77,777 | −$422,223 | −84.44% |
| Q1 2019 | 2019-03-31 | $2.0M | $2.0M | — |
| Q4 2018 | 2018-12-31 | $292,238 | — | — |
| Q3 2018 | 2018-09-30 | $99,835 | $99,835 | — |
| Q2 2018 | 2018-06-30 | $500,000 | — | — |
| Q1 2018 | 2018-03-31 | $0 | — | — |
| Q3 2017 | 2017-09-30 | $0 | — | — |
| Q3 2015 | 2015-09-30 | $0 | $0 | — |
| Q2 2015 | 2015-06-30 | $0 | $0 | — |
| Q3 2014 | 2014-09-30 | $0 | — | — |
| Q2 2014 | 2014-06-30 | $0 | — | — |
Panacea Life Sciences Holdings stock-based compensation trends
Over the last five fiscal years, Panacea Life Sciences Holdings's stock-based compensation increased from $5,000 to $1.4M, a change of $1.3M. The latest reported quarter, Q1 2021, shows −$3.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Panacea Life Sciences Holdings source filings ↗